Clinical trials: Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Viral Infection
Analysis of Human to Human Transmission of Middle East Respiratory Syndrom Coronavirus (MER-CoV)
This study aimed to analysis the characteristics of MERS transmission and the effect of our institutional personal protective equipment on the controlling the MERS at a tertiary Korean Hospital.
- Trial name
- MKU (NCT02605109)
- Testing
- Risk of MERS infection
- Volunteers
- 200 people
- Sponsor
- Konkuk University Medical Center
COVID-19, Coronavirus Infections
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant
VBI-2901e is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and…
- Trial name
- NCT05614245
- Testing
- VBI-2901e
- Where
- 4 sites in Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Influenza, Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV)
Respiratory Virus Hospitalization Study (FLU 003 Plus)
Following the sudden and unexpected emergence of influenza A(H1N1)pdm09 (2009 H1N1) virus, this observational study was initiated to estimate rates of morbidity and mortality and to examine predictors of severity among…
- Conditions
- Influenza, Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
- Trial name
- NCT01056185
- Where
- 63 sites in United States, Argentina and 10 more
- Volunteers
- 1,000 people
- Sponsor
- University of Minnesota
COVID-19, Coronavirus Infections
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a
VBI-2901a is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and…
- Trial name
- NCT05548439
- Testing
- VBI-2901a
- Where
- 7 sites in Canada
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Healthy
Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers
The Middle East Respiratory Syndrome Coronavirus (MERS CoV), a virus related to Severe Acute respiratory syndrome coronavirus (SARS CoV), was first recognized as a cause of severe pulmonary infection in 2012.
- Trial name
- NCT02670187
- Testing
- GLS-5300
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
MERS (Middle East Respiratory Syndrome), MERS
Study of Safety and Immunogenicity of BVRS-GamVac-Combi
The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 during the first Middle East respiratory syndrome (MERS) outbreak.
- Trial name
- NCT04128059
- Testing
- BVRS-GamVac-Combi
- Where
- Russia
- Volunteers
- 268 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Middle East Respiratory Syndrome Coronavirus
Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults
Background: Middle East Respiratory Syndrome (MERS) is a newly discovered contagious and sometimes fatal respiratory virus. People often get MERS through close contact with an infected person.
- Trial name
- NCT02788188
- Testing
- SAB-301, Normal (9%) Saline
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
MERS (Middle East Respiratory Syndrome)
Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)
This is a clinical trial in which healthy volunteers will be administered an experimental MERS vaccine. The vaccine ChAdOx1 MERS will be administered alone both as a single administration and with a homologous prime-booster.
- Trial name
- NCT03399578
- Testing
- ChAdOx1 MERS
- Where
- United Kingdom
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Healthy
Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers
The Middle East Respiratory Syndrome Coronavirus (MERS CoV), is a cause of severe and highly fatal lower respiratory tract infection, first identified in 2012.
- Trial name
- NCT03721718
- Testing
- GLS-5300, Cellectra 2000 Electroporation
- Where
- 2 sites in South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
Coronavirus Infections
Seroprevalence of MERS-CoV IgG in Healthcare Workers
The investigators aim to do serosurvey of healthcare-personnel who had participated in treatment of confirmed patients of Middle-East respiratory syndrome.
- Trial name
- NCT02497885
- Where
- South Korea
- Volunteers
- 737 people, healthy volunteers welcome
- Sponsor
- Ewha Womans University Mokdong Hospital
Influenza and Other Novel Respiratory Viruses
Respiratory Virus Outpatient Study (FLU 002 Plus)
Following the sudden and unexpected emergence of influenza A(H1N1)pdm09 (2009 H1N1) virus, this observational study was initiated to describe participants seeking medical care in geographically diverse locations with 2009 H1N1…
- Trial name
- NCT01056354
- Where
- 68 sites in United States, Argentina and 13 more
- Volunteers
- 11,719 people
- Sponsor
- University of Minnesota
Corona Virus Infection, Middle East Respiratory Syndrome (MERS)
Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease
The aim of the study is to clinically use bovine Lf as a safe antiviral adjuvant for treatment and to assess the potential in reducing mortality and morbidity rates in COVID-19 patients.
- Conditions
- Corona Virus Infection, Middle East Respiratory Syndrome (MERS), Acute Respiratory Distress Syndrome, Coronavirus Infection
- Trial name
- COVID-19_LF (NCT04412395)
- Testing
- Lactoferrin (Apolactoferrin)
- Where
- 4 sites in Egypt
- Volunteers
- 516 people
- Sponsor
- National Research Centre, Egypt
Corona Virus Infection
A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051
This is a Phase 1, first-in-human (FIH), single site, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single ascending doses of a…
- Trial name
- NCT03301090
- Testing
- REGN3048, REGN3051
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
MERS (Middle East Respiratory Syndrome)
Safety and Immunogenicity of the Candidate Vaccine MVA-MERS-S_DF-1 Against MERS
The study will be a two center, randomized, double blind, placebo controlled study of the MVA MERS S_DF-1 candidate delivered by i.m. injection.
- Trial name
- MVA-MERS-S (NCT04119440)
- Testing
- MVA-MERS-S_DF1 - Low Dose, MVA-MERS-S_DF1 - High Dose
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
MERS (Middle East Respiratory Syndrome), MERS
Study of Safety and Immunogenicity of BVRS-GamVac
The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 during the first Middle East respiratory syndrome (MERS) outbreak.
- Trial name
- NCT04130594
- Testing
- BVRS-GamVac
- Where
- Russia
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers
The purpose of this Phase 2a, randomized, blinded, placebo-controlled, multi-center study is to evaluate the safety, tolerability and immunogenicity of INO-4700 administered by intradermal (ID) injection followed by…
- Trial name
- NCT04588428
- Testing
- INO-4700, CELLECTRA™ 2000
- Where
- 6 sites in Jordan, Kenya and 1 more
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
Respiratory Distress Syndrome (& [Hyaline Membrane Disease])
Anti-MERS-CoV Convalescent Plasma Therapy
Since the first report of the Middle East Respiratory Syndrome Corona virus (MERS- CoV) in September 2012, more than 800 cases have been reported to the World Health Organization (WHO) with substantial mortality.
- Trial name
- NCT02190799
- Testing
- Convalescent plasma
- Where
- Saudi Arabia
- Sponsor
- King Abdullah International Medical Research Center
COVID 19
Colostrum From MERS-CoV Seropositive Camels for SARS-CoV-2 Infection - a Placebo-controlled Randomized Trial.
The study aims to study the efficacy of colostrum from MERS-CoV-positive camels applied as a nasal spray to COVID-19 patients for treatment and prevention of SARS-CoV-2 infection.
- Trial name
- NCT06857318
- Testing
- Colostrum Nasal Spray, Water for injection
- Where
- Israel
- Volunteers
- 43 people
- Sponsor
- Hadassah Medical Organization
Middle East Respiratory Syndrome Coronavirus
A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine (MERS002)
A phase Ib study to determine the safety and immunogenicity of the candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) vaccine ChAdOx1 MERS in healthy adult Middle Eastern volunteers
- Trial name
- NCT04170829
- Testing
- ChAdOx1 MERS
- Where
- Saudi Arabia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- King Abdullah International Medical Research Center
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b
This is a placebo-controlled clinical trial to assess the efficacy and safety of a combination of lopinavir/ritonavir and Interferon beta-1b in hospitalized patients with MERS.
- Trial name
- MIRACLE (NCT02845843)
- Testing
- Combination of Lopinavir /Ritonavir and Interferon beta-1b
- Where
- 2 sites in Saudi Arabia
- Volunteers
- 95 people
- Sponsor
- King Abdullah International Medical Research Center